Skip directly to content

Corporate Sponsorships January - December 2012

on Wed, 06/08/2016 - 22:34

*all amounts listed exclude GST

Alzheimer's Australia

Alzheimer's Australia is the peak body providing support and advocacy for the 269,000 Australians with dementia and the million Australians who care for them. The organisation supplies information, support, education, counselling and helpline services and provides leadership in policy and services. Through Alzheimer's Australia, research grants are provided to emerging researchers. Alzheimer's Australia's vision is for a society committed to the prevention of dementia whilst valuing and supporting people living with the condition.
 
Pfizer Australia provided funding to Alzheimer's Australia for:

  • The National Consumer Advocacy Committee. This Committee is made up of people living with dementia, their families and carers. The broad purpose of the Committee is to build a consumer focus into the work of Alzheimer's Australia and its State and Territory member organisations ($20,000)
  • The CEO of Alzheimer's Australia to attend the Alzheimer's Disease International (ADI) Conference in March 2012 ($5,000)
  • Dementia Awareness Week 2012 ($20,000)
  • Consumer surveys prioritised by the National Consumer Advocacy Committee ($5,000)
  • Marketing and media campaign with a focus on risk reduction factors for dementia ($100,000)


Total: $150,000
 
Arthritis Australia

Nearly one in five Australians (3.85 million people) has arthritis. They are represented by Arthritis Australia, the peak arthritis organisation in Australia and supported by Affiliate offices in each State and Territory. Arthritis Australia provides support and information to people living with arthritis, as well as their carers, families and friends.
 
Arthritis Australia provides customised programs, delivered to GPs, allied health professionals and community workers both in metropolitan and rural areas. In addition, Arthritis Australia promotes awareness and advocates for improvements for Australians living with arthritis to business leaders, Federal politicians, their advisers, and Government officials. Through the Arthritis Australia National Research Program, emerging researchers receive funding support to progress their work in gaining a greater understanding of arthritis and associated musculoskeletal conditions, as well as the long-held hope for a cure.
 
In 2012 Pfizer Australia supported the Medicines Australia Community Chest for Arthritis Australia, with funding of $15,000. This included a GP survey, conducted by METIS Healthcare Research which was funded with an untied grant from the Medicines Australia Community Chest for Arthritis Australia. The GP survey was carried out in late 2011 and included two phases: qualitative, where doctors' beliefs and opinions were ascertained in focus groups and a quantitative questionnaire to a national sample of 200 GPs, 24% of whom were in rural or regional locations. The survey also asked GPs to recall and discuss the last patient they saw with arthritis.
 
In addition, Pfizer Australia supported the printing and distribution costs of the consumer information booklet, ‘Taking control of your osteoarthritis’ with an untied grant of $8,000.
 
Total: $23,000

Arthritis NSW

Arthritis NSW was established over 40 years ago to provide education, support and services to people in the community living with arthritis and other musculoskeletal conditions. More than 3.85 million Australians have arthritis. Arthritis NSW supports people of all ages and provides information to people who have been newly diagnosed with the disease, as well as those who have lived with it for some time.
 
Arthritis NSW also works with health care professionals to improve the management of arthritis, and supports research into the causes and treatment of arthritis.
 
In 2012 Pfizer supported Arthritis NSW as an Event Sponsor. The key 2012 events were Splash for Arthritis, William's Walk and William's Ball.
 
Total: $40,000

Australian Haemophilia Centre Directors' Organisation (AHCDO)

Australian Haemophilia Centre Directors' Organisation (AHCDO). AHCDO is the national medical body for haemophilia in Australia. AHCDOs objectives are:

  • to advance care and treatment of people with haemophilia in Australia;
  • to advance the education of the medical profession and the broad range of health professionals associated with people with haemophilia in the knowledge of haemophilia and its treatment;
  • to promote haemophilia research, and to disseminate the results of such research;
  • to liaise with, and provide information and advice to Haemophilia Foundation Australia, Federal, State and Territory Governments, and other such bodies involved in the welfare of people with haemophilia in Australia.

In 2012 Pfizer Australia supported AHCDO by providing funds for the Australian Bleeding Disorder Registry Data Managers to attend the World Federation of Haemophilia Conference July 8-12, in Paris. The congress is the pre-eminent meeting on bleeding disorders providing the data managers an invaluable educational opportunity and also the chance to network and learn from other professionals who are experts in dealing with bleeding disorders around the globe ($15,000).
 
Pfizer Australia also provided support to AHCDO for their clinical excellence fund (CEF). The CEF is an internal fund managed by an Advisory Committee, made up of 4 AHCDO members that act as trustees, and distribute the funds to support peer reviewed research proposals and other research projects. ($10,000)
 
Total: $25,000

The Australian Lung Foundation Incorporated

The Australian Lung Foundation Incorporated was established in 1990 by a group of thoracic physicians concerned about the chronic shortage of funds for research work in respiratory medicine and the impact of lung disease on our community. The Australian Lung Foundation's mission is to 'ensure lung health is a priority for all in Australia'. This is achieved through the provision of leadership, advocacy, information, support and research, patient and carer support and education and training.
 
In 2012 Pfizer supported a number of programs and initiatives including

  • the Lung Cancer National Program
  • the Australian Lung Cancer Conference 2012 (ALCC)
  • the Australasian Lung Cancer Trials Group (ALTG)
  • the Australia and New Zealand – Lung Cancer Nurses Network (ANZ-LCNF)
  • the Kylie Johnston Lung Cancer Network (KJLCN)

The Lung Foundation's Respiratory infectious diseases group through provision of sponsorship of the Bronchiectasis Registry Project
Pfizer was also a proud sponsor of World Chronic Obstructive Pulmonary Disease (COPD) Day, 2011.
 
Total: $102,090

Australian Pain Management Association (APMA)

Australian Pain Management Association (APMA) is a QLD-based national consumer association supporting individuals with chronic pain, and their families. APMA was established to meet the need for improved information, support and services for people living with persistent pain, and to provide a voice for these people, their carers and families. Living with, and managing pain needs medical advances, as well as reliable and current medical and lifestyle support information, activities and support to restore function and quality of life to individuals whose main disability is pain.
 
Pfizer Australia provided funding to the APMA for the publication of four quarterly newsletters. The content was developed by APMA volunteers. The newsletters were distributed to APMA members and health professionals who work in the area of managing chronic pain ($11,816).
 
A "Working with your GP" patient information brochure was also developed showing patients how to work with their multidisciplinary primary care team to achieve the best health outcomes ($7,000).
 
Funds were also provided to APMA to put towards their Helpline Education Meeting ($636).
 
Total: $19,452 

Australian Pituitary Foundation Ltd 

The Australian Pituitary Foundation Ltd (APF) was founded in Sydney in 1994 by pituitary patients and family members, with the endorsement of Australian endocrinologists, neurosurgeons, radiation therapists and endocrine nurses, who saw the need to support people who have rare conditions of the pituitary gland.  After five years the APF developed into a company with benevolent status, limited by guarantee.
 
The APF's mission is to provide support to those who have experienced pituitary gland conditions. They promote awareness and disseminate information among the medical community, public, pituitary patients and their families.
 
In 2012 Pfizer Australia supported the APF by funding:
 
National patient educational seminars and dedicated GP and health professional education in North Queensland which aimed to improve health outcomes of patients with rare pituitary disorders
The development and maintenance of the APF's website
Total: $22,000

Australian Rheumatology Association

The Australian Rheumatology Association supports and educates members and other practitioners in the musculoskeletal field to enable provision of best possible management for patients. It fosters excellence in the diagnosis and management of musculoskeletal and inflammatory conditions through training, professional development, research and advocacy.
 
In 2012 Pfizer supported the development of the Australian Rheumatology Association Database registry (ARAD).  ARAD collects important health information from individuals with inflammatory arthritis such as:

  • Rheumatoid arthritis
  • Ankylosing spondylitis
  • Juvenile arthritis
  • Psoriatic arthritis

Total: $50,000

Carers Australia

Pollie Pedal is a cycling event started in 1998 by a number of federal and state politicians. Its purpose is to raise money for various charities whilst giving smaller Australian communities the opportunity to meet various Members of Parliament. Carers Australia was the beneficiary of the 2012 Pollie Pedal.
 
Carers Australia will use the proceeds of Pollie Pedal to break down the isolation experienced by carers by connecting them with each other, with the community and with supports and services to assist carers in their caring role. Specifically Carers Australia will use the funds to: 

  • Build a hub for engagement and sharing information for and about Australia's carers
  • Support community engagement using Carer Ambassadors to promote and communicate carer issues within the wider community
  • Undertake a study to find practical ways to overcome isolation for Indigenous carers
  • Increase employer understanding of the importance of workplace participation and flexibility for carers

Total: $12,910

The Collaboration for Health in Papua New Guinea (CHPNG)

The Collaboration for Health in Papua New Guinea (CHPNG) is a collaboration of pharmaceutical companies that provide support for projects that aid the fight against HIV/AIDS in PNG. The Collaboration has made significant steps forward in HIV/AIDS care in PNG.  To date, funding has been provided for:

  • Workshops held across PNG, attended by over 250 doctors, nurses, health administrators, counsellors and lab technicians
  • From 2008 until the present, more than 10 Australian HIV specialists have mentored 80 PNG colleagues across eight provinces on HIV/AIDS treatment and care
  • Over 3,000 people in PNG are currently receiving HIV care through CHPNG supported sites
  • Over 50,000 people have accessed counselling and testing
  • The member companies of the CHPNG are BMS, Boehringer Ingelheim, Gilead, Janssen, MSD, Pfizer and ViiV Healthcare.

 
Total: $20,000

Chronic Pain Australia

Chronic Pain Australia is a health promotion charity based in Sydney. Its mission is to reduce the unnecessary suffering and isolation caused by chronic pain in the Australian community. Its core objectives are to: destigmatise chronic pain through developing advocacy programs, prevent isolation (by developing support and information services) and improve knowledge about chronic pain for the whole community including people in pain and their families, as well as health professionals (by organising educational initiatives).
 
In 2012 Pfizer supported Chronic Pain Australia's second National Pain Week. Chronic Pain Australia developed National Pain Week to create awareness and to educate people living with pain and their carers, treatment providers, governments and the general public. Pfizer supported this media campaign which focused on issues faced by people in pain, controlling pain, treatment options and counselling.
 
Total: $50,000

Cure our Kids

Since 2001, Cure Our Kids' mission has been to restore normalcy to the lives of children with cancer and the families who love them at The Children's Hospital at Westmead. They deliver a range of support services to help families cope with the many challenges childhood cancer presents. This ensures that families, in turn, have the strength and resilience to give their sick child the emotional support they need.
 
Pfizer Australia supported Cure our Kids with funding for the development of the 2012 and 2013 treatment diaries. The diaries are used by families as a resource that stores vital information in one place for all treatment protocols throughout the year.
 
Total: $5,000

Haemophilia Foundation Australia (HFA)

Haemophilia Foundation Australia (HFA) represents people with haemophilia, von Willebrand disorder and other related inherited bleeding disorders, and their families through:

  • Advocacy and Representation
  • Education
  • Research
  • HFA works with a network of state and territory foundations and specialist health professionals groups to ensure all people with bleeding disorders in Australia have access to the world's best practice treatment and care. HFA is a National Member Organisation of the World Federation of Haemophilia and participates in activities to improve access to treatment and care to people with bleeding disorders around the world.

 
In 2012 Pfizer:

  • Supported the Vision and Leadership Awards: $11,000. The Awards were established by HFA to provide new opportunities and encouragement for people affected by a bleeding disorder to identify and achieve personal development or community leadership goals.
  • Sponsored the Corporate Partner Program: $40,000. This provides support to HFA for the benefit of the Australian bleeding disorders community for its education, advocacy and research activities.

Total: $51,000

Haemophilia Foundation of Western Australia Inc

The aim of the Haemophilia Foundation of Western Australia Inc. is to work towards a better quality of life for people with a bleeding disorder and to provide support for their families.
 
In 2012 Pfizer supported the Western Australia Family Camp.
 
Total: $545.45

Heart Foundation

The Heart Foundation Pharmaceutical Roundtable (the Roundtable) brings together members of leading pharmaceutical companies to help improve the cardiovascular health of Australians. Since its inception, the Roundtable has contributed about $4 million towards advancing cardiovascular research. This collaboration also offers members a unique opportunity to participate in and develop new evidence based consumer health education and prevention projects together with the Heart Foundation, with a particular focus on Quality Use of Medicines (QUM) and adherence.
 
The Heart Foundation acknowledges the Roundtable as a unique opportunity to provide sector leadership and a productive alliance, delivering mutual benefits to the member companies and the Heart Foundation as well as improved health outcomes for the public.
 
The operating principles of the Roundtable are based on:

  • openness
  • transparency
  • fairness
  • achieving and maintaining trust and
  • respect for the Heart Foundation's independence.

The Heart Foundation Research Program operates independently of the Pharmaceutical Roundtable. The Research Program allocates funding using an independent peer review process, where external committees review and rank all the applications received for research funding every year. These committees are made up of experienced researchers and academics from around the country who are experts in cardiovascular disease. This process ensures the Heart Foundation operates in a fair and transparent manner, only funding the highest quality research applications received.
 
In 2012 Pfizer provided funding towards The Heart Foundation Pharmaceutical Roundtable membership. The Roundtable promotes the Quality Use of Cardiovascular Medicines. In 2012 the Roundtable launched an online education program for GPs, Pharmacists and Nurses to identify non-adherence with cardio-vascular medicines in patients. This program was developed in conjunction with the University of Sydney.
 
Total: $20,000

Kidney Health Australia

Kidney Health Australia is a not-for-profit organisation whose focus is to improve kidney health outcomes leading to substantial improvements to the quality of life for people with kidney and urinary tract diseases, their families and carers. Kidney Health Australia also develops initiatives that reduce the incidence of kidney disease in the Australian community.
 
In 2012 Pfizer Australia provided funding towards a national 3 month awareness campaign on Improvement of Outcomes for Kidney Cancer Patients that commenced on 1 September 2012.
 
Total: $15,000

The Meningitis Centre

The Meningitis Centre is an Australian not-for-profit organisation based in Perth, Western Australia. It was established in 1992 by a group of parents and health care professionals who recognised the need to raise public awareness of meningitis and its various forms.
 
The Meningitis Centre strives to eliminate meningitis in Australia. It has produced materials for educating the community across Australia to be aware of the signs and symptoms of this disease. It also provides crucial support for families affected by the disease. With Meningitis, every second counts. In 2012 Pfizer Australia continued its support of the Meningitis Centre by providing funds to go towards raising the awareness of the impact of Meningitis nationally.
 
Total: $65,000

Mental Health Council of Australia (MHCA)

The Mental Health Council of Australia (MHCA) is the peak, national non-government organisation representing and promoting the interests of the Australian mental health sector, committed to achieving better mental health for all Australians. Its mission is to achieve better mental health in Australia through strategic engagement in policy, practice and research.
 
In 2012 Pfizer supported MHCA by funding the MHCA Pharma Collaboration. The Collaboration aims to operate under the guidelines and principles set out in the document Working Together: A Guide for Relationships between Health Consumer Organisations and Pharmaceutical Companies.
 
The MHCA Pharma Collaboration's mission statement is: 'The Pharmaceutical Industry and MHCA working together to support consumers, carers and health professionals to improve the quality of mental health care and outcomes for people with mental health problems by promoting the development and effective implementation of mental health policy.'
 
In 2012-13 Pfizer has provided funding towards the following MHCA Collaboration projects:

  • Quality Use of Medicines project.
  • Indigenous Co-morbidity Publication and Launch.
  • World Mental Health Day Parliament House Breakfast.
  • Support for the World Mental Health Day awareness campaign.

Total: $27,000

Osteoporosis Australia

Osteoporosis affects 1.2 million Australians and a further 5.4 million have low bone density (a possible precursor to osteoporosis). Osteoporosis Australia is a national, not-for-profit organisation committed to improving the awareness and understanding of osteoporosis and better bone health. The organisation aims to reduce the incidence of osteoporosis, and osteoporotic fractures, in the Australian community and provides information and services to consumers and health professionals nationally.
 
In 2012 Pfizer Australia provided support to Osteoporosis Australia. This support is acknowledged on Pfizer products related to bone health.
 
Total: $63,000

Painaustralia

Painaustralia is the national not-for-profit organisation which aims to improve the quality of life of people living with pain and their families, to minimise the burden of pain on individuals and the community by working with consumers, health care professionals and State and Federal Governments to implement the recommendations of the National Pain Strategy. The National Pain Strategy is the result of 18 months work by over 150 healthcare professionals, people who live with pain, and not-for-profit bodies representing a broad range of health issues, including chronic diseases associated with pain, such as arthritis and cancer.
 
In 2011 Painaustralia established the 'Painaustralia Collaboration' with Pfizer Australia and other leading pharmaceutical companies. The main aim of this collaboration is to raise awareness of chronic pain as a disease in its own right and promote the need for improved pain services.
 
In 2012, the focus of Painaustralia was to raise awareness of the problem of chronic pain and the National Pain Strategy; maintain information services to members and the broader community; evaluate and maintain existing education resources for consumers; maintain a register of pain related research and participate where possible.
 
In 2012 Pfizer Australia contributed $57,500 to the collaboration.

Prader-Willi Syndrome Association of Victoria

The Prader-Willi Syndrome Association of Victoria was established in 1978 by parents of children affected by the syndrome and is run entirely by volunteers. PWSA Victoria is a support group that provides awareness, education and support to families living with Prader-Willi Syndrome to ensure better quality of life for persons with PWS and their families. Their members include parents and carers, family members, people with PWS, medical professionals, educators and interested supporters.
 
In 2012 Pfizer Australia supported PWSA Victoria through 2 initiatives.
Sponsoring a speaker to talk about PWS at their PWSA support day.
Annual support of the PWSA newsletters

Total: $7,000

Pulmonary Hypertension Association Australia (PHAA)

PHAA is a not-for-profit volunteer organisation supporting patients suffering from Pulmonary Hypertension along with their families and carers. PHAA's mission is to provide hope, support and education, to promote awareness and to advocate for the pulmonary hypertension community.
 
Pfizer Australia provided PHAA with a grant to support PHA Australia's Secretary to attend the 10th International Pulmonary Hypertension Conference in Orlando Florida in June 2012.
 
Total: $2,000

Pulmonary Hypertension Society of Australia  and New Zealand (PHSANZ)

The Pulmonary Hypertension Society of Australia and New Zealand is a 'Not for Profit' organisation with a mandate to advocate for a sustainable 'model of care' with equitable access to skilled clinicians that allows timely diagnosis, treatment and ongoing management for patients with Pulmonary Hypertension in Australia and New Zealand.
 
Pulmonary Hypertension is a relatively rare disease considered to be present in between 15 – 55 patients per million people of the general population in its rarest form of Pulmonary Arterial Hypertension (PAH). This has substantively increased from historical data suggesting only 1-2 patients per million in the general population. Pulmonary Hypertension is however more of an 'umbrella' disease encompassing more common forms of associated Pulmonary Hypertension affecting much larger numbers of patients. Recent Australian data suggests that pulmonary hypertension, in all its forms, may affect up to 5,000 people per million or 500 in every 100,000 people in Australia. The primary symptom in patients presenting to primary care is 'shortness of breath' (SOB). SOB is a universal symptom which may reflect any number of more common underlying diseases, e.g. Asthma, Congestive Cardiac Failure, Coronary Heart Disease, Chronic Lung Diseases, Anaemia and many more making the diagnosis of the much more rare disease of PAH difficult.
 
In 2012 Pfizer Australia supported the PHSANZ across multiple projects that included:

  • The national scientific meeting
  • Phase II of the implementation and execution of the ANZ registry of PHT patients
  • Development of an awareness and breathlessness campaign
  • Pilot program for nurses looking at sustainable models of care in PHT management

Total: $50,000

Sexual Health And Family Planning Australia

Sexual Health and Family Planning Australia (SH&FPA) has been a leader in shaping the health rights agenda through advocacy, networking and capacity building at the national and international levels for over 30 years. As a not-for-profit organisation with charitable status, they work collaboratively with other national and international non-government organisations, governments and the private sector to achieve improved sexual and reproductive health and rights. SH&FPA is the national peak body for the sexual health and family planning organisations (their Member Organisations). Collectively, they provide a range of sexual and reproductive health clinical services, community education programs, professional training and research.
 
In 2012 Pfizer Australia provided an untied funding grant to support Sexual Health and Family Planning Australia's important initiative 'The Inaugural Australian Sexual and Reproductive Health Research (SRHR) Roundtable'. The goal of the Research Roundtable was to strengthen national research in SRHR that will contribute to an enhanced policy focus on SRHR issues at both government and non-government levels.
 
Total: $22,000

Royal Australian and New Zealand College of Ophthalmologists (RANZCO) and The Eye Foundation

The Eye Foundation is the medical eye specialists' foundation, dedicated to restoring sight and preventing vision loss throughout Australasia. The Eye Foundation is a not-for-profit eye health organisation. It represents more than 890 Australian and New Zealand medical eye specialists (ophthalmologists) who are passionate about giving future generations the best vision possible.
 
The Foundation was founded in 2002 as the fundraising arm of The Royal Australian and New Zealand College of Ophthalmologists (RANZCO) and The Ophthalmic Research Institute of Australia (ORIA).
 
In 2012 Pfizer Australia supported the Eye Foundation by funding ANZRAG medical research, educational scholarships, the JulEYE awareness campaign and sponsoring the RANZCO 2012 Congress.
 
Pfizer also provided funding to the Eye Foundation for the Myanmar Eye Care Program. The money was put towards the costs of Doctors travelling to regional Myanmar to perform surgical procedures.
 
Total: $297,400

The Skin & Cancer Foundation

The Skin & Cancer Foundation is a not-for-profit, DGR registered, non government funded organisation which provides specialist treatment for a wide variety of skin diseases with an overall aim of skin health led by dermatologists.
 
The Foundation houses the Australasian Psoriasis Registry (APR) and the specialist Occupational Dermatology Research and Education Centre (ODREC), the latter providing over two thirds of contact dermatitis patch testing in Australia.
 
In 2012 Pfizer provided funding to the Australasian Psoriasis Registry. The overall aim of the APR is to develop and maintain a national web-based database that will provide valid and reliable longitudinal clinical data of psoriasis sufferers in Australia, with the ultimate aim of providing better care and improving outcomes for patients.
 
In consultation with College Fellows, overseas centres and a local software designer, the following was developed:

  • web-based online application that will allow clinicians or nurses to securely enter data from any location with internet access
  • A centralised administration to provide user access, quality control of data and facilitate auditing and reporting.

Total: $30,000

Tour De Cure

The Tour de Cure (TDC) is a cycling foundation committed to raising money to help fund vital cancer research, support and prevention projects. Through engaging Australian communities their aim is to raise awareness and inspire action in the fight against cancer. Tour de Cure's signature annual cycling Tour celebrates their fundraising efforts and sees a group of ordinary people embark on an extraordinary journey.
 
In 2012 the Tour de Cure rode from Brisbane to Mission Beach in Queensland (10 days, 1700km).
 
In 2012 Pfizer colleagues participated in the Tour de Cure and helped share the TDC 'BE FIT, BE HEALTHY, BE HAPPY 'cancer prevention message with over 10,000 families.
 
Pfizer Oncology's 2012 sponsorship of the Tour de Cure was $60,000. This funding covered:

  • Team and Category Jersey Partnership at the four Tour de Cure Tours: 
  • VIC Cancer Awareness for Country Tour (4 Days 550km) March 2012 
  • TDC 2012 Signature Tour Brisbane to Mission Beach (11 Days 1700km) May 2012
  • QLD Cancer Awareness for Country Tour (4days 520km) October 2012
  • NSW Cancer Awareness for Country Tour (4days 570km) November 2012
  • Category Jersey – Purple Jersey for Cure for Life Foundation (awarded daily on each Tour)
  • Gold Partner of "A Day of Inspiration 2012" held in Sydney & Brisbane February 2012
  • Primary Partner of the TDC adult cancer awareness book "What I wish I knew about Cancer"
  • Staff engagement: 1 Tour rider (Vic Country Tour) and 5 guest riders (TDC Signature Tour) positions for the 2012 TDC Events
  • Team naming rights on riders' jerseys

Total: $60,000.

The Unicorn Foundation

The Unicorn Foundation is the only Australian not-for-profit medical charity focussed on neuroendocrine tumours (NET). The Unicorn Foundation aims to educate and support Australian sufferers of NET and their families by increasing their awareness and knowledge of the disease. It also aims to direct donations to Australian researchers and institutions who will work towards a cure for this rare group of cancers.
 
In 2012 the Unicorn Foundation continued its partnership with Pfizer Australia, Novartis and Ipsen. The aim of this collaboration is to increase awareness and build knowledge about neuroendocrine cancers. This awareness-raising campaign will focus on:

  • Developing educational material for GPs and Patients
  • Promoting the Unicorn Foundation as a peak body, a resource and an advocacy group
  • Support World NET Awareness Day

In 2012 Pfizer Australia contributed $16,000.